|
|
Vol. 54, No. 2, February 2008, pp.253 - 254 Copyright © 2008 by The College of Family Physicians of Canada
Defying dementiaDavid B. Hogan, MD FACP FRCPCBrenda Stratford Foundation Chair in Geriatric Medicine at the University of Calgary in Alberta AUTHOR Robert Levine, PUBLISHER Praeger Publishers, 88 Post Rd W, Westport, CT 06881, USA; TELEPHONE 203 226-3571; WEBSITE www.praeger.com, PUBLISHED 2006/232 pp/$34.95 (US)
OVERALL RATING Poor STRENGTHS Interesting and important topic WEAKNESSES Unsupported statements; inappropriate language for intended audience AUDIENCE Intelligent lay-people Defying Dementia is a disappointing offering that doesnt adequately serve the needs of its intended audience of "intelligent lay people" who want to learn about dementia and its prevention. While recent research indicates we might be able to delay the onset of dementia by treating vascular risk factors and following a healthy lifestyle, the author goes beyond the available data to make unwarranted statements. Levine does not deal well with the potential of harm arising from some of his suggestions. I cant recommend this book to either the general public or family physicians. The first part of Defying Dementia deals with dementia, its confounders, and causes. It is too long, taking up approximately two-thirds of the book. The terminology used is more appropriate for a medical audience. How many well-educated lay readers would even understand terms like "amyloid beta derived diffusible ligands" and abbreviations such as APOE-4, PSEN1, or PSEN2? Family physicians who want an introduction to the various forms of dementia would be better served by a recent review article such as "The primary care of Alzheimer disease" by C.D. Rubin.1 The lifestyle recommendations, though difficult to argue against, have not been proven as ways to prevent dementia. We already have convincing reasons for patients to be more active and to follow a healthier diet. I have greater concerns about other suggestions; for example, Levine states that daily acetylsalicylic acid is "one of the major weapons in our arsenal in the battle against ... dementia." Yet the observational data for this is inconclusive.2 In fact, a controlled trial examining whether ASA prevented cognitive decline was negative.3 And no mention is made of the increased risk for both hemorrhagic strokes and gastrointestinal bleeding with ASA.4 When advising individuals on disease prevention, we must be confident that well see the greatest good for the greatest number. We arent there yet for the prevention of dementia.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||